Biomarkers.

Background: A decline in Instrumental Activities of Daily Living (IADLs) indicates cognitive impairment, a marker of early detection of Alzheimer's disease (AD). Obtaining hand information within the assessment of IADLs may be an innovative approach to predicting cognitive decline. Hands play a vital role while performing IADL and can be used in assessing human visuomotor skills.

Dementia Care Research and Psychosocial Factors.

Background: The World Health Organization forecasts a population of 2,000 million people over 60 years by the year 2050, with 7% of this population suffering from dementia. Making a constant clinical-technological evaluation of older adults allows early detection of the disease and provides a better quality of life for the patient. In this sense, the research and development of innovative technological systems for the early detection of the disease, its monitoring and management of the growing number of patients with cognitive diseases has increased in recent years, integrating data collection and its automatic processing based on geriatric metrics into these systems using artificial intelligence (AI) methods.

The Potential of Automated Assessment of Cognitive Function Using Non-Neuroimaging Data: A Systematic Review.

The growing incidence of cognitive impairment among older adults has a significant impact on individuals, family members, caregivers, and society. Current conventional cognitive assessment tools are faced with some limitations. Recent evidence suggests that automating cognitive assessment holds promise, potentially resulting in earlier diagnosis, timely intervention, improved patient outcomes, and higher chances of response to treatment.

Avelumab to treat Merkel cell carcinoma: real-life experience in a dedicated oncology center.

The arrival of immunotherapy has revolutioned the management of patients with metastatic Merkel cell carcinoma (MCC). We conducted an observational, retrospective study of 14 cases treated with avelumab. The response rate was 57%: complete response was reached in 29% of patients, and partial responses in 29%.